ARDT vs NBIX · P/E 8.5, rev $6.32B vs P/E 45, rev $1.77B
Ardent Health Partners, Inc. (ARDT) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Ardent Health Partners, Inc. (ARDT) is a medical care facilities company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ARDT revenue for 2025-12-31 was $6.32B. Net income was $135.8M. Revenue was up 6.0% from 2024-12-31 to 2025-12-31. ARDT currently screens at market cap $2.10B and trailing P/E 8.5.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
ARDT currently screens at market cap $2.10B and trailing P/E 8.5. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the ARDT and NBIX stock pages for the full models.
Not investment advice.